Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL3706558 | 0.88 | ALDH1A1 (0.52) | EGFRPIK3CDPIK3CAALDH1A1KDM4E | |
| Acridine SCHEMBL3851263 | 0.86 | ALDH1A1 (0.47) | EGFRPIK3CDPIK3CAALDH1A1KDM4E | |
| Isoquinoline SCHEMBL3607434 | 0.84 | EGFR (0.43) | EGFRPIK3CDPIK3CAALDH1A1KDM4E | |
| Purine SCHEMBL2120547 | 0.82 | KDM4A (0.38) | EGFRALDH1A1KDM4EGLAGAA | |
| Purine SCHEMBL29456595 | 0.82 | — | — | |
| Purine SCHEMBL3157 | 0.82 | — | — | |
| Purine SCHEMBL6421376 | 0.82 | KDM4A (0.38) | EGFRALDH1A1KDM4EGLAGAA | |
| Quinazoline SCHEMBL11972093 | 0.82 | EGFR (0.67) | EGFRPIK3CDPIK3CAALDH1A1KDM4E | |
| Benzimidazole SCHEMBL14678248 | 0.82 | KDM4E (0.40) | EGFRALDH1A1KDM4EGLAGAA | |
| Quinazoline SCHEMBL27407620 | 0.80 | EGFR (0.91) | EGFRPIK3CDPIK3CAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102675316-A | Quinazoline purine derivative and application thereof in preparation of diabetes drugs | SUZHOU BORUI BIOLOG PHARMACEUTICAL TECHNOLOGY CO LTD | 2012-09-19 | — | — | CN | claimed |
| EP-2847279-B1 | SURFACE MODIFIED PIGMENT PARTICLES, METHOD OF PREPARATION AND APPLICATION THEREOF | SUN CHEMICAL CORP (US) | 2018-11-28 | — | — | EP | disclosed |
| EP-3378901-A1 | SURFACE MODIFIED CARBON BLACK PIGMENT PARTICLES AND APPLICATION THEREOF | Sun Chemical Corporation (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9073863-B2 | Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150118494-A1 | SURFACE MODIFIED PIGMENT PARTICLES, METHOD OF PREPARATION & APPLICATION THEREOF | SUN CHEMICAL CORPORATION | 2015-04-30 | — | — | US | disclosed |
| EP-2847279-A1 | SURFACE MODIFIED PIGMENT PARTICLES, METHOD OF PREPARATION AND APPLICATION THEREOF | Sun Chemical Corporation (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20140296215-A1 | Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2013169395-A1 | SURFACE MODIFIED PIGMENT PARTICLES, METHOD OF PREPARATION AND APPLICATION THEREOF | SUN CHEMICAL CORPORATION (US) | 2013-11-14 | — | — | WO | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2012166654-A1 | CYANOQUINOLINE COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND INCREASING ION TRANSPORT AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-06 | — | — | WO | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| CN-1390220-A | Kinase inhibitors as therapeutic agents | ABBOTT AG (DE) | 2003-01-08 | — | — | CN | disclosed |
| CN-1390219-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT AG (DE) | 2003-01-08 | — | — | CN | disclosed |
| EP-1268481-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019828-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296215-A1 | Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof | CFTR, SLC47A1, SLC47A2 | EGFR 3452/4885PIK3CD 1583/4885PIK3CA 1086/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | EGFR 2229/4885PIK3CD 1497/4885PIK3CA 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.